Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer’s Disease Missed Primary Endpoint – StreetInsider.com

November 23, 2016 by  
Filed under Alzheimers News

Sponsored By
Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
StreetInsider.com
Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated with …

and more »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*